• News
  • BioTech

Cadence Pharmaceuticals terminates option agreement to acquire Incline Therapeutics

San Diego-based Cadence Pharmaceuticals Inc. (Nasdaq: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, has entered into an agreement to terminate its exclusive option to acquire privately-held Incline Therapeutics Inc.

To continue reading, subscribe now
log in to your account
User Response
0 UserComments
Subscribe Today!